You just read:

Actinium Highlights Actimab-A Phase 2 Trial Results in Older Patients with Unfit AML from ASH Annual Meeting Demonstrating Single Agent Activity of the CD33 Antibody Radiation Conjugate

News provided by

Actinium Pharmaceuticals, Inc.

Dec 03, 2018, 08:00 ET